FDA delays a decision on MS pill cladribine until February

11/28/2010 | Reuters

Merck KGaA said the FDA has extended for three months a priority review of cladribine, an oral treatment for relapsing multiple sclerosis. The announcement comes two months after the company failed to obtain European approval for the drug.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN